Suppr超能文献

相似文献

1
Characterization of Gene Alterations following Editing of the β-Globin Gene Locus in Hematopoietic Stem/Progenitor Cells.
Mol Ther. 2018 Feb 7;26(2):468-479. doi: 10.1016/j.ymthe.2017.11.001. Epub 2017 Nov 9.
2
3
CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells.
Mol Ther. 2016 Sep;24(9):1561-9. doi: 10.1038/mt.2016.148. Epub 2016 Jul 29.
6
Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells.
Blood. 2015 Apr 23;125(17):2597-604. doi: 10.1182/blood-2014-12-615948. Epub 2015 Mar 2.
7
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells.
Nature. 2016 Nov 17;539(7629):384-389. doi: 10.1038/nature20134. Epub 2016 Nov 7.
8
Base editing of haematopoietic stem cells rescues sickle cell disease in mice.
Nature. 2021 Jul;595(7866):295-302. doi: 10.1038/s41586-021-03609-w. Epub 2021 Jun 2.
9
Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus.
Blood. 2018 Apr 26;131(17):1960-1973. doi: 10.1182/blood-2017-10-811505. Epub 2018 Mar 8.
10
Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing.
Blood. 2018 Jun 28;131(26):2915-2928. doi: 10.1182/blood-2018-03-838540. Epub 2018 May 22.

引用本文的文献

1
Hematopoietic stem cell gene therapy for the treatment of X-linked agammaglobulinemia.
Mol Ther Methods Clin Dev. 2025 Aug 12;33(3):101555. doi: 10.1016/j.omtm.2025.101555. eCollection 2025 Sep 11.
2
[Advancements in CRISPR-Cas9 for Fanconi anemia].
Zhonghua Xue Ye Xue Za Zhi. 2025 Mar 14;46(3):276-280. doi: 10.3760/cma.j.cn121090-20240825-00321.
3
Non-viral DNA delivery and TALEN editing correct the sickle cell mutation in hematopoietic stem cells.
Nat Commun. 2024 Jun 11;15(1):4965. doi: 10.1038/s41467-024-49353-3.
4
Genome editing for sickle cell disease: still time to correct?
Front Pediatr. 2023 Nov 2;11:1249275. doi: 10.3389/fped.2023.1249275. eCollection 2023.
5
Clinical genome editing to treat sickle cell disease-A brief update.
Front Med (Lausanne). 2023 Jan 9;9:1065377. doi: 10.3389/fmed.2022.1065377. eCollection 2022.
6
Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease.
Cells. 2022 Jun 4;11(11):1843. doi: 10.3390/cells11111843.
7
High-level correction of the sickle mutation is amplified during erythroid differentiation.
iScience. 2022 May 10;25(6):104374. doi: 10.1016/j.isci.2022.104374. eCollection 2022 Jun 17.
8
A Small Key for a Heavy Door: Genetic Therapies for the Treatment of Hemoglobinopathies.
Front Genome Ed. 2021 Feb 4;2:617780. doi: 10.3389/fgeed.2020.617780. eCollection 2020.
9
Impact of a grant program to spur advances in sickle cell disease research.
Blood Adv. 2021 Oct 12;5(19):3855-3861. doi: 10.1182/bloodadvances.2021005709.
10
Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing.
Int J Mol Sci. 2021 Jun 10;22(12):6275. doi: 10.3390/ijms22126275.

本文引用的文献

4
CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells.
Mol Ther. 2016 Sep;24(9):1561-9. doi: 10.1038/mt.2016.148. Epub 2016 Jul 29.
5
Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases.
Nat Rev Genet. 2016 May;17(5):300-12. doi: 10.1038/nrg.2016.28.
6
A genome editing primer for the hematologist.
Blood. 2016 May 26;127(21):2525-35. doi: 10.1182/blood-2016-01-678151. Epub 2016 Apr 6.
9
miRNA-embedded shRNAs for Lineage-specific BCL11A Knockdown and Hemoglobin F Induction.
Mol Ther. 2015 Sep;23(9):1465-74. doi: 10.1038/mt.2015.113. Epub 2015 Jun 17.
10
Measuring and Reducing Off-Target Activities of Programmable Nucleases Including CRISPR-Cas9.
Mol Cells. 2015 Jun;38(6):475-81. doi: 10.14348/molcells.2015.0103. Epub 2015 May 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验